[EN] ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C<br/>[FR] POLYTHÉRAPIE ANTICANCÉREUSE AVEC UN INHIBITEUR DE N-(1-ACRYLOYL-AZÉTIDIN-3-YL)-2-((1H-INDAZOL-3-YL) AMINO) MÉTHYL)-1 H-IMIDAZOLE-5-CARBOXAMIDE DE KRAS-G12C
申请人:TAIHO PHARMACEUTICAL CO LTD
公开号:WO2021215545A1
公开(公告)日:2021-10-28
A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.
治疗癌症的方法包括向需要此类治疗的受试者施用:(a) 公式(I)的化合物或其药用可接受的盐的治疗有效量;和(b) 另一种抗癌药物的治疗有效量,其中公式(I)的化合物为:其中X、R1、R2、环A、L1、L2、L3和R5的定义如本公开说明书中所定义。